Cargando…

Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical Trials

IMPORTANCE: Accumulation of disability in multiple sclerosis may occur as relapse-associated worsening (RAW) or steady progression independent of relapse activity (PIRA), with PIRA regarded as a feature of primary and secondary progressive multiple sclerosis. OBJECTIVE: To investigate the contributi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kappos, Ludwig, Wolinsky, Jerry S., Giovannoni, Gavin, Arnold, Douglas L., Wang, Qing, Bernasconi, Corrado, Model, Fabian, Koendgen, Harold, Manfrini, Marianna, Belachew, Shibeshih, Hauser, Stephen L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2020
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281382/ https://www.ncbi.nlm.nih.gov/pubmed/32511687 http://dx.doi.org/10.1001/jamaneurol.2020.1568

Ejemplares similares

Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension
por: Hauser, Stephen L., et al.
Publicado: (2020)

Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis
por: Barkhof, Frederik, et al.
Publicado: (2019)

Risk of requiring a walking aid after 6.5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis: Data from the OPERA I and OPERA II trials
por: Giovannoni, Gavin, et al.
Publicado: (2021)

Safety of Ocrelizumab in Patients With Relapsing and Primary Progressive Multiple Sclerosis
por: Hauser, Stephen L., et al.
Publicado: (2021)

Blood neurofilament light levels predict non-relapsing progression following anti-CD20 therapy in relapsing and primary progressive multiple sclerosis: findings from the ocrelizumab randomised, double-blind phase 3 clinical trials
por: Bar-Or, Amit, et al.
Publicado: (2023)

Chronic white matter lesion activity predicts clinical progression in primary progressive multiple sclerosis
por: Elliott, Colm, et al.
Publicado: (2019)

Evaluation of no evidence of progression or active disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial
por: Wolinsky, Jerry S., et al.
Publicado: (2018)

Teriflunomide reduces relapses with sequelae and relapses leading to hospitalizations: results from the TOWER study
por: Miller, Aaron E., et al.
Publicado: (2014)

Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis
por: Turner, Benjamin, et al.
Publicado: (2019)

Greater sensitivity to multiple sclerosis disability worsening and progression events using a roving versus a fixed reference value in a prospective cohort study
por: Kappos, Ludwig, et al.
Publicado: (2017)

Slowly expanding/evolving lesions as a magnetic resonance imaging marker of chronic active multiple sclerosis lesions
por: Elliott, Colm, et al.
Publicado: (2018)

Overall Disability Response Score: An integrated endpoint to assess disability improvement and worsening over time in patients with multiple sclerosis
por: Chang, Ih, et al.
Publicado: (2022)

Relapse recovery in relapsing–remitting multiple sclerosis: An analysis of the CombiRx dataset
por: Koch, Marcus W, et al.
Publicado: (2023)

No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1a
por: Havrdová, Eva, et al.
Publicado: (2018)

Effects of Dimethyl Fumarate on Brain Atrophy in Relapsing-Remitting Multiple Sclerosis: Pooled Analysis Phase 3 DEFINE and CONFIRM Studies
por: Nakamura, Kunio, et al.
Publicado: (2022)

Recurrent disability progression endpoints in multiple sclerosis clinical trials
por: Bühler, Alexandra, et al.
Publicado: (2022)

Bodies out of control: Relapse and worsening of eating disorders in pregnancy
por: Sommerfeldt, Bente, et al.
Publicado: (2022)

Treatment and Relapse Prevention of Typical and Atypical Optic Neuritis
por: Saitakis, George, et al.
Publicado: (2022)

Teriflunomide reduces relapse-related neurological sequelae, hospitalizations and steroid use
por: O’Connor, Paul W., et al.
Publicado: (2013)

Ocrelizumab in relapsing and primary progressive multiple sclerosis: Pharmacokinetic and pharmacodynamic analyses of OPERA I, OPERA II and ORATORIO
por: Gibiansky, Ekaterina, et al.
Publicado: (2020)

Effect of delayed‐release dimethyl fumarate on no evidence of disease activity in relapsing–remitting multiple sclerosis: integrated analysis of the phase III DEFINE and CONFIRM studies
por: Havrdova, E., et al.
Publicado: (2017)

A randomized trial of teriflunomide added to glatiramer acetate in relapsing multiple sclerosis
por: Freedman, MS, et al.
Publicado: (2015)

Development, validation and clinical usefulness of a prognostic model for relapse in relapsing-remitting multiple sclerosis
por: Chalkou, Konstantina, et al.
Publicado: (2021)

Siponimod: Disentangling disability and relapses in secondary progressive multiple sclerosis
por: Cree, Bruce AC, et al.
Publicado: (2020)

Relapses
Publicado: (1858)

Molecular and immunological analyses of confirmed Plasmodium vivax relapse episodes
por: Maneerattanasak, Sarunya, et al.
Publicado: (2017)

Teriflunomide slows BVL in relapsing MS: A reanalysis of the TEMSO MRI data set using SIENA
por: Radue, Ernst-Wilhelm, et al.
Publicado: (2017)

Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis
por: Kuhle, Jens, et al.
Publicado: (2015)

The cost of relapse and the predictors of relapse in the treatment of schizophrenia
por: Ascher-Svanum, Haya, et al.
Publicado: (2010)

Association of Higher Ocrelizumab Exposure With Reduced Disability Progression in Multiple Sclerosis
por: Hauser, Stephen L., et al.
Publicado: (2023)

Pre-specified subgroup analyses of a placebo-controlled phase III trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis
por: Miller, Aaron E, et al.
Publicado: (2012)

Varicella-zoster virus encephalitis mimicking toxoplasmosis relapse
por: Marques, Inês Brás, et al.
Publicado: (2015)

Cladribine Tablets for Relapsing–Remitting Multiple Sclerosis: A Clinician’s Review
por: Giovannoni, Gavin, et al.
Publicado: (2022)

Melanoma sentinel node biopsy and prediction models for relapse and overall survival
por: Mitra, A, et al.
Publicado: (2010)

Relapsing Polychondritis
por: Sosada, Beata, et al.
Publicado: (2014)

Relapsing Eczema
Publicado: (1908)

Relapsing Fever
por: Ali, Musharraf
Publicado: (1918)

Relapsing Polyneuritis
por: Pirzada, M. A.
Publicado: (1951)

Relapsing Fever
Publicado: (1871)

Plague Relapses
Publicado: (1898)

Cannot write session to /tmp/vufind_sessions/sess_6udissmvblrm4dmedurpmgjskf